Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy: Practical Importance of Anti-α-Actinin Immunostaining.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
06
11
2021
accepted:
05
04
2022
entrez:
17
5
2022
pubmed:
18
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
Sporadic late-onset nemaline myopathy (SLONM) is a treatable or otherwise fatal myopathy. Diagnosis of SLONM is still challenging, and no therapeutic consensus has been achieved. Here, we reported the clinicopathologic features and long-term follow-up data of SLONM in a Chinese cohort. We performed a retrospective evaluation of clinical, pathologic, and treatment outcomes of 17 patients with SLONM diagnosed between March 1986 and April 2021 at our neuromuscular center. Immunohistochemistry (IHC) with antibodies against 5 Z-disc-associated proteins was performed in the muscle biopsies of SLONM to identify a potential pathologic marker in aid of diagnosis. In comparison, we also performed muscle IHC in patients with selective type II fiber atrophy (n = 22), neurogenic atrophy (n = 22), mitochondrial myopathy (n = 5), immune-mediated necrotizing myopathy (n = 5), and normal controls (n = 5). Most of the patients exhibited asymmetric limb muscles weakness (71%, 12/17) and neck extensor weakness (53%, 9/17). Immunofixation electrophoresis was performed in 11 patients, and 4 of them were identified with monoclonal gammopathy of undetermined significance (MGUS). EMG from 16 patients demonstrated a myopathic pattern with spontaneous activities in 69% (11/16) of them. Muscle MRI showed preferential involvement of paraspinal, gluteus minimus and medius, semimembranosus, and soleus muscles. Suspected nemaline bodies on modified Gomori trichrome were confirmed by IHC using anti-α-actinin antibody (100%, 17/17), anti-myotilin antibody (94%, 16/17), anti-desmin antibody (94%, 16/17), anti-α-B crystallin antibody (65%, 11/17), and anti-telethonin antibody (18%, 3/17) with various positive rates. Notably, anti-α-actinin IHC showed the highest percentage of strongly positive staining (77%, 13/17), being the only one without negative results. Moderate improvement following autologous stem cell transplantation (ASCT) was noted in 3/4 patients with MGUS; favorable outcomes were also achieved in 6/7 patients without MGUS, including 3 patients with complete recovery who were given a combined treatment of prednisone and another immunosuppressant. SLONM is a treatable myopathy with ASCT or traditional immunotherapy, especially when combined with steroids and immunosuppressants. Anti-α-actinin immunostaining is the most reliable pathologic marker to identify rod-bearing fibers, and it should be performed routinely in adult patients with undiagnosed nonnecrotic myopathies.
Sections du résumé
BACKGROUND AND OBJECTIVES
Sporadic late-onset nemaline myopathy (SLONM) is a treatable or otherwise fatal myopathy. Diagnosis of SLONM is still challenging, and no therapeutic consensus has been achieved. Here, we reported the clinicopathologic features and long-term follow-up data of SLONM in a Chinese cohort.
METHODS
We performed a retrospective evaluation of clinical, pathologic, and treatment outcomes of 17 patients with SLONM diagnosed between March 1986 and April 2021 at our neuromuscular center. Immunohistochemistry (IHC) with antibodies against 5 Z-disc-associated proteins was performed in the muscle biopsies of SLONM to identify a potential pathologic marker in aid of diagnosis. In comparison, we also performed muscle IHC in patients with selective type II fiber atrophy (n = 22), neurogenic atrophy (n = 22), mitochondrial myopathy (n = 5), immune-mediated necrotizing myopathy (n = 5), and normal controls (n = 5).
RESULTS
Most of the patients exhibited asymmetric limb muscles weakness (71%, 12/17) and neck extensor weakness (53%, 9/17). Immunofixation electrophoresis was performed in 11 patients, and 4 of them were identified with monoclonal gammopathy of undetermined significance (MGUS). EMG from 16 patients demonstrated a myopathic pattern with spontaneous activities in 69% (11/16) of them. Muscle MRI showed preferential involvement of paraspinal, gluteus minimus and medius, semimembranosus, and soleus muscles. Suspected nemaline bodies on modified Gomori trichrome were confirmed by IHC using anti-α-actinin antibody (100%, 17/17), anti-myotilin antibody (94%, 16/17), anti-desmin antibody (94%, 16/17), anti-α-B crystallin antibody (65%, 11/17), and anti-telethonin antibody (18%, 3/17) with various positive rates. Notably, anti-α-actinin IHC showed the highest percentage of strongly positive staining (77%, 13/17), being the only one without negative results. Moderate improvement following autologous stem cell transplantation (ASCT) was noted in 3/4 patients with MGUS; favorable outcomes were also achieved in 6/7 patients without MGUS, including 3 patients with complete recovery who were given a combined treatment of prednisone and another immunosuppressant.
DISCUSSION
SLONM is a treatable myopathy with ASCT or traditional immunotherapy, especially when combined with steroids and immunosuppressants. Anti-α-actinin immunostaining is the most reliable pathologic marker to identify rod-bearing fibers, and it should be performed routinely in adult patients with undiagnosed nonnecrotic myopathies.
Identifiants
pubmed: 35581006
pii: 9/4/e1184
doi: 10.1212/NXI.0000000000001184
pmc: PMC9128036
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Actinin
11003-00-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Muscle Nerve. 2013 Dec;48(6):983-8
pubmed: 23873431
JAMA Neurol. 2015 Sep;72(9):996-1003
pubmed: 26192196
Eur J Transl Myol. 2020 Sep 16;30(3):9225
pubmed: 33117509
J Muscle Res Cell Motil. 2019 Jun;40(2):111-126
pubmed: 31228046
Int J Cancer. 2021 Jun 1;148(11):2807-2814
pubmed: 33529362
Neurology. 2008 Aug 12;71(7):472-3
pubmed: 18695157
Neurotherapeutics. 2021 Oct;18(4):2397-2418
pubmed: 34766257
Acta Neuropathol Commun. 2014 Oct 23;2:154
pubmed: 25339355
Neurology. 2008 Aug 12;71(7):531-2
pubmed: 18565830
Neuromuscul Disord. 2018 Jul;28(7):610-613
pubmed: 29910095
J Neurol. 2018 Mar;265(3):542-551
pubmed: 29356967
N Engl J Med. 2015 Apr 30;372(18):1734-47
pubmed: 25923553
Bone Marrow Transplant. 2018 Jul;53(7):895-899
pubmed: 29367711
Neuromuscul Disord. 1993 Sep-Nov;3(5-6):557-60
pubmed: 8186711
Arch Neurol. 1992 May;49(5):440
pubmed: 1316119
J Neuropathol Exp Neurol. 1975 Mar;34(2):119-32
pubmed: 47386
Nat Rev Rheumatol. 2018 May;14(5):303-318
pubmed: 29651119
Mayo Clin Proc. 1966 Nov;41(11):713-41
pubmed: 5957590
Neurology. 2019 Jul 16;93(3):e298-e305
pubmed: 31167932
Int J Cancer. 2021 Jun 1;148(11):2638-2639
pubmed: 33577708
N Engl J Med. 1987 Dec 17;317(25):1602-3
pubmed: 3683496
J Infect Dis. 1997 Oct;176(4):924-32
pubmed: 9333150
Orphanet J Rare Dis. 2017 May 11;12(1):86
pubmed: 28490364
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Intern Med. 2021 Jul 15;60(14):2327-2332
pubmed: 33612671
Eur Heart J Case Rep. 2020 Dec 22;5(1):ytaa480
pubmed: 33554019
Neuromuscul Disord. 2021 Jan;31(1):29-34
pubmed: 33308940
Brain Pathol. 2021 May;31(3):e12962
pubmed: 34043258
Neurology. 2005 Oct 25;65(8):1158-64
pubmed: 16148261